Welcome to Bio-Link
Bio-Link is a life sciences commercialisation company which facilitates partnerships based on technology review, project management, business development and deal negotiation. Bio-Link has offices in Sydney and Melbourne.
Our clients include Australian biotech companies and medical research institutes as well as organisations located outside Australia. Our portfolio extends across small molecule and peptide drug candidates, genetic and protein biomarkers, gene and cell therapies, immunotherapies and other leading technologies.
Bio-Link adds value to the commercialisation process through critical assessment of patents, packaging of pre-clinical and clinical data, technology marketing and identification and engagement with potential collaborators, licensees, or investors.
Our team has experience in therapeutics and diagnostics and has been involved in a number of commercial transactions in the USA, Europe and Australia.
Please explore this website to gain more information about our team, our clients and our portfolio.
|
|
|
|
21st June 2010 - Bio-Link Engaged by TGR Biosciences
Bio-Link has been engaged by TGR Biosciences to assist in the commercialisation of Lactermin™, a milk-derived bioactive protein extract developed for the prevention and treatment of oral mucositis and general mouth care applications, and TGR-313, a buttermilk-derived bioactive protein extract developed for prevention of allergic disorders in infants and young children.
17th February 2010 - Bio-Link Engaged by QRxPharma
Bio-Link has been engaged by QRxPharma to assist in partnering the TorsinA Drug Discovery Program for Protein Misfolding Diseases. Lead indications are Parkinson's disease and early-onset torsion dystonia. QRxPharma is the exclusive licensee of the Program, which is located at the University of Alabama.
10th February 2010 - Deal Announcement
Bio-Link has facilitated an alliance between Mui Scientific and Toouli Omari Catheter Company around a next generation sleeve spinchter of Oddi manometry catheter technology.
23rd July 2009 - Deal Announcement
Bio-Link has facilitated an alliance between Bayer Animal Health GmbH and Murdoch University around small molecule drug candidates for the possible treatment of protozoan parasitic infections of companion animals and livestock.